TAVIST-1
LOE ApproachingNDAORALTABLET
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVIST-1 is an oral tablet NDA approved by Novartis in 1977 with unknown mechanism of action and indication profile. The drug's mechanism, pharmacologic class, and therapeutic indications are not publicly available in the provided data.
LOE Approaching
As a legacy asset approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle management and planning for generic erosion rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAVIST-1 currently shows zero linked job openings, reflecting its mature, declining commercial stage. Working on this product offers limited upward mobility and career development, with focus shifting toward generic transition management and cost containment rather than strategic innovation.
Brand ManagerProduct Manager
Worked on TAVIST-1 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.